

## Webinar on IMI 2 – Call 18 Supporting the development of engineered T cells

### Participant list

26.06.2019

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Cristina	Abad	IIS La Fe	Spain	cristina_abad@iislafe.es	-
Kasimu	Adoke	Department of pathology Ahmadu Bello University	Nigeria	kasimuadoke@gmail.com	Although it is for research purposes, long time application and publication on reputable journal should be encouraged
Lee	Aiyegbusi	University of Birmingham	United Kingdom	O.L.Aiyegbusi@bham.ac.uk	Qualitative and quantitative research expertise and experience in Patient Public Involvement (PPI) research
Miriam	Alb		Germany	alb_m@ukw.de	Expertise in CAR T cell research and Tumor Immunology
Nathalie	Amzallag	Institut Curie	France	nathalie.amzallag@curie.fr	Program management in immunotherapy in the Center for Institut Curie. Potential partner in CAR T cell pre-clinical development.
Michael	Apel	Miltenyi Biotec GmbH	Germany	michaela@miltenyibiotec.de	CAR T engineering and manufacturing expertise, analytics, monitoring, QC, regulatory and translational expertise
Joaquin	Arribas	Vall d'Hebron Institute of Oncology (VHIO)	Spain	jarribas@vhio.net	CARs against novel breast tumor-specific antigens, animal models and 3D cultures, patient-derived tumor xenografts
Luca	Battistelli	Istituto Scientifico romagnolo per lo studio e la cura dei Tumori Srl IRST IRCCS	Italy	luca.battistelli@irst.emr.it	I'm a gran office manager

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Reuben	Benjamin	Kings College Hospital	United Kingdom	reuben.benjamin@kcl.ac.uk	Clinical experience with CAR-T cell therapy and experience with allogeneic CAR-T cells
Riccardo	Bertini	Innovation ACTA S.r.l.	Italy	bertini@innovationacta.eu	Project Management, Dissemination and Communication Activities
Karine	Breckpot	Vrije Universiteit Brussel	Belgium	karine.breckpot@vub.be	mRNA, nanobodies
Christopher	Carey	Institute of Cellular Medicine, Newcastle University	United Kingdom	Christopher.Carey@newcastle.ac.uk	Scientific lead for a CAR-T registration study in the UK.
Andrés	Cervantes	Biomedical Research Institute INCLIVA	Spain	andres.cervantes@uv.es	Experience in developmental therapeutics and innovative approaches for cancer trials in humans
Lisa	Chakrabarti	Institut Pasteur	France	chakra@pasteur.fr	Ressource: T cell receptors preferentially expressed in natural HIV controllers; Expertise: lentiviral TCR transfer
Renzo	Cortez	UNMSM	Peru	RCORTEZ95@HOTMAIL.com	dsdsd s
Mihai	Craciun	Faculty of medicine	Romania	mcraciun02@yahoo.com	I do not know now.
Rajdeep	Das	UCSF	United States	rajdeep.das@ucsf.edu	I am clinically trained pathologist and have extensive expertise on CRISPR technology
Marco	Davila	H. Lee Moffitt Cancer Center and Research Institute	United States	marco.davila@moffitt.org	pre-clinical modeling of CAR T toxicity and efficacy as well as clinical correlative analyses of clinical CAR T cell samples
Gennaro	De Libero	University of Basel	Switzerland	gennaro.delibero@unibas.ch	Experimental models, cell lines, TCR genes, cellular and molecular immunology expertise
Erica	Delucchi	CRG	Spain	erica.delucchi@crg.eu	Biomedical research
Nick	Devoogdt	Vrije Universiteit Brussel	Belgium	ndevoogdt@vub.be	nanobodies, RNA transduction

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Farid E.	Director	GEM Tox Labs, Institute for Research in Biotechnology	United States	instresbiotech@yahoo.com	Experience
Antonia	Diukendjieva	Institute for Medical Research	Bulgaria	antonia.diukendjieva@imresearch.co	Clinical trial services; Patients' recruitment for validation studies; HTA services; Medical and scientific writing and editing
Emmanuel	Donnadieu	INSERM	France	emmanuel.donnadieu@inserm.fr	Preclinical models to assess safety and efficacy of CAR T cells
Caroline	Dreuillet	Institut National du Cancer (INCa)	France	cdreuillet@institutcancer.fr	INCa has a relevant expertise in the field of communication tools for patients and coordination regarding the use of CAR-T cells
Natalia	Elizalde	VIVEbiotech	Spain	nelizalde@vivebiotech.com	Company fully specialized in LVs with expertise in CAR-T/TCR projects
Carlos	Fernandez de Larrea	Hospital Clinic de Barcelona	Spain	cfeman1@clinic.cat	One year at the MSKCC in the development of preclinical CAR T cells for multiple myeloma. Institutional CAR T cells in Barcelona
christophe	FERRAND	EFSBFC - INSERM - UFC	France	christophe.ferrand@efs.sante.fr	CART development from academic structure
Astrid	Flandorfer	FFG	Austria	astrid.flandorfer@ffg.at	...
Anne	GALY	Inserm	France	anne.galy@inserm.fr	Development of processes for the manufacture of engineered T cells for trials, standardization of specific analytical methods
Beatriz	Garcia Fernandez	Instituto Gulbenkian de Ciência	Portugal	beatrizf@igc.gulbenkian.pt	research in T lymphocyte development both under steady state and in leukemia
Pascal	Gelebart	University of Bergen	Norway	pascal.gelebart@uib.no	Pre-clinical models to assess safety and efficacy of CAR T cell therapies

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Macdara	Glynn	Curran Scientific	Ireland	macdara@curranscientific.com	Engineering experience and expertise in the development of novel automation technologies for cell and molecular biology.
Emmanuel	Gomez	Carnot CALYM Institute	France	emmanuel.gomez@calym.org	R&D Lymphoma expertise from basic science to clinical practice + CAR T dedicated units (CALYM = LYSA, LYSARC, 17 academic labs)
Oscar	Gonzalez	Clinica Universidad de Navarra	Spain	ogonmor@unav.es	We have an Adoptive Cell Therapy research program which includes CAR-T from bench to bedside, along with a GMP lab
Alena	Gros	VHIO	Spain	agros@vhio.net	My group focuses developing T-cell therapies targeting neoantigens and other tumor antigens to treat cancer patients
Amra	Grudic-Feta	University of Bergen	Norway	amra.grudic@uib.no	Support staff
Sonia	Guedan	IDIBAPS	Spain	sguedan@clinic.cat	I have 9 years of experience with CAR-T cells for the treatment of solid tumours. I can make key contributions in WP4-5
Dr. Manal	Hadenfeld	Miltenyi Biotec GmbH	Germany	manalh@miltenyibiotec.de	Analytical methods, immune monitoring, pre-clinical testing, regulatory aspects of CAR-T cell manufacturing, imaging
Stephen	Haley	Immudex	United States	sh@immudex.com	Immudex manufactures a reagent for the detection of antigen-specific T cells. Our GMP grade Dextramer is being used in TCR-T
Darren	Heeke	Kite Pharma/Gilead	United States	dheeke@kitepharma.com	T cell functional and phenotypic characterization
Anders	Holm	Zelluna Immunotherapy AS	Norway	anders.holm@zelluna.com	TCR-Ts for treatment of solid tumors, allogeneic TCR-NK technology, pre-clinical/translational/manufacturing expertise

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
William	Howell	TheraSentient BioPharma	United States	whowell@therasentient.com	We are developing a platform technology for localized delivery of immunomodulatory molecules.
Enrica	Imbrogno	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori IRCCS	Italy	enrica.imbrogno@irst.emr.it	I will support the researchers in the project design and management.
jocelyn	jakubik			jocelyn.jakubik@precisionformedicine.com	Perform Nanostring for pharma clients in oncology; testing service, offer ability to integrate all biomarker data in QuartzBio
Valerie	Janelle	Université de Montréal	Canada	valerie.janelle@umontreal.ca	Expertise in antigen-specific T-cell generation/clinically-compliant culture protocols/T-cell biology (cellular dysfunction).
Hao	Jiang			hao.jiang@bms.com	Tech
Janine	Jost	European Research and Project Office GmbH	Germany	j.jost@eurice.eu	Project management expertise/activities, dissemination and communication (internal, external) expertise/activities
Manel	Juan	IDIBAPS	Spain	mjuan@clinic.cat	We have a CART19 Academic clinical trial with our own CAR
Aino	Kalervo	TILT Biotherapeutics	Finland	aino@tiltbio.com	Experience in T-cell work w/out lymphodepletion for example
Ceyda	Kekeç		Turkey	ckekec@gmail.com	R&D, T-cell, stem cell
Susan	Kentner	German Cancer Research Center (DKFZ)	Germany	s.kentner@dkfz.de	The DKFZ Grants Office supports its scientists in applying for third-party funding and administering projects.
Gudrun	Koch			gudrun.koch@kl.ac.at	-
Paul	Leonard	Dublin City University	Ireland	paul.leonard@dcu.ie	Patented digital cell biology platform called DiCAST that can analyse millions of single cells in parallel.

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Cristina	Maccalli	Sidra Medicine	Qatar	cmaccalli@sidra.org	Expert in functional characterization of anti-tumor T cells, identify novel target antigens and multidimensional platforms
Imre	Mager	University of Oxford	United Kingdom	imre.mager@paediatrics.ox.ac.uk	Extracellular vesicles
Elena	Martí	INCLIVA	Spain	ejimenez@incliva.es	We manage different kind of cancers and we have the expertise of analysing drug efficiency/resistance, including immunotherapies
Beatriz	Martin Antonio	IDIBAPS	Spain	bmartina@clinic.cat	We have experience in developing CART cells, broad experience in NK cells, inflammation and innate immunity.
Denis	Martinvalet	Univeristy of Padova	Italy	Denis.martinvalet@unipd.it	Expertise in cytotoxic lymphocyte function
Bechara	Mfarrej	Institut Paoli-Clmettes	France	mfarrejb@ipc.unicancer.fr	Experience in cell therapy product development
Tanja	Miletic	AIT, Austrian Institute of Technology	Austria	tanja.miletic@ait.ac.at	Project management
David	Morrow	EATRIS	Netherlands	davidmorrow@eatris.eu	Research Infrastructure including 45 top tier EU institutions covering the entire ATMP production and development pipeline
Thomas	Nerreter	Universitätsklinikum Würzburg	Germany	Nerreter_T@ukw.de	CAR T cell design and optimization
Catarina	Neves	CINTESIS - Center for Health Technology and Services Research	Portugal	catarinamneves@med.up.pt	CINTESIS is a research unit with a health research scope (www.cintesis.eu) at the Faculty of Medicine of the UPorto.
Virginia	Nieto Guerrero	International Project Office of the Andalusian Public Health System-	Spain	virginia.nieto@juntadeandalucia.es	Expertise and resources

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
		Fundación Progreso y Salud			
Ismaela	Nieuwenhuijs	Erasmus University Medical Centre	Netherlands	i.nieuwenhuijs@erasmusmc.nl	Expertise in fundamental research areas, health challenges, public health and prevention, excellent research infrastructure.
Jelena	Ochs	Fraunhofer IPT	Germany	jelena.ochs@ipt.fraunhofer.de	Automation for manufacture of cell and gene therapy
FATMA VISAL	OKUR	Hacettepe University	Turkey	fvokur@hacettepe.edu.tr	To start producing CAR_T cells in our GMP Facility, and an initiative for cellular immunotherapies in Turkey
CECILE	PELTEKIAN	INSTITUT PASTEUR	France	cecile.peltekian@pasteur.fr	Representative - Institut Pasteur Immunology Departement expertise
DAVID	PENG	Genovo Corporation	United States	dpeng@genovodx.com	research ideas
Alejandro	Piris Giménez	Vall d'Hebron Institute of Oncology	Spain	apiris@vhio.net	Translational and clinical research on immunology and immunotherapies, incipient in car-T cells
Angela	Ponce Polo	Andalusian Network for Design And Traslation of Advanced Therapies	Spain	angela.ponce@juntadeandalucia.es	Preclinical expertise, clinical development, GMP manufacturing, regulatory, exploitation and dissemination
Tristan	Pritchard-Meaker	Cell and Gene Therapy Catapult	United Kingdom	tristan.pritchard-meaker@ct.catapult.org.uk	Cell and gene therapy industrialisation support including development laboratories and consultancy resources
Kylie	Quinn	RMIT University	Australia	kylie.quinn@rmit.edu.au	Expertise on T cell ageing- datasets on age-related phenotypic, transcriptional, functional, epigenetic and metabolic changes.
Doris	Rakoczy	AIT Austrian Institute of Technology GmbH	Austria	doris.rakoczy@ait.ac.at	biosensors, systems integration, point-of-care devices, bioinformatics, biomarker discovery & validation, biological barriers...
Vedashree	Ramakrishnaiah	Erasmus Medical Center	Netherlands	v.ramakrishnaiah@erasmusmc.nl	I work as a EU funding advisor. I help research with planning and preparing proposals for EU calls

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Jochen	Rauch	Fraunhofer IBMT	Germany	jochen.rauch@ibmt.fraunhofer.de	ICT solutions for e-health, personal health systems, semantic biomedical data integration, biobanking, clinical cancer research
Álvaro	Ritoré Hidalgo	Andalusian Network for Design and Translation of Advanced Therapies	Spain	alvaro.ritore@juntadeandalucia.es	Preclinical expertise, Clinical development, Manufacturing capacities
Loredana	SAVEANU	INSERM	France	loredana.saveanu@inserm.fr	We had a basic science project on the TCR trafficking and signalling and would like to apply its results to CAR receptors.
Margarida	Serra	IBET-Instituto de Biologia Experimental e Tecnológica	Portugal	mserra@ibet.pt	Bioprocess development for production and purification of ATMP (cells, lentivirus), analytical tools for ATMP characterization
Wenge	Shi	Navigate BP	United States	wenge.shi@navigatebp.com	Planning for project, assay validation, clinical trial support
Carin	Smand	European Hematology Association	Netherlands	c.smand@ehaweb.org	Expertise and a relevant network on communication, dissemination & training
Rafael	Solana	Andalusian Network for Advanced Therapies (ANdtAT). Regional Ministry of Health	Spain	rafael.solana.lara@juntadeandalucia.es	ANdtAT coordinates research and clinical application of advanced therapies, including CARs, in the Andalusian Regional Ministry
Frauke	Stähler	RESTORE	Germany	frauke.staehler@charite.de	RESTORE aims curing chronic diseases by making the transformative promise of Advanced Therapies reality for patients benefit
Einar	Sulheim	SINTEF	Norway	einar.sulheim@sintef.no	In vitro high throughput screening, product characterization and analysis.
Arpad	Szoor	University of Debrecen	Hungary	akuka@med.unideb.hu	Generation and testing (in vitro and in vivo) of CAR, BiTE and CAAR modified immune (T; primary NK and NK-92) or stem cells.



Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Divya	Thiagarajan	Karolinska Institutet	Sweden	divya.thiagarajan@ki.se	Having a strong immunology background, I can contribute to technical expertise in this field.
Kris	Thielemans	Vrije Universiteit Brussel	Belgium	Kris.Thielemans@vub.be	mRNA based T cell engineering, nanobody technology, immuno-oncology, cell therapy, mRNA technology-GMP production
D.B.R.K. Gupta	Udatha	Oslo Cancer Cluster	Norway	gupta.udatha@oslocancercluster.no	Cluster Network, SME Innovation, Academic and Clinician Groups, Event Management, Communication, Dissemination, Exploitation
patrick	van houts	nanosting	Netherlands	pvanhouts@nanosting.com	my contacts/research partners in benelux. nanosting gene-expression transcriptomics , plus mass spec other omics experience
Leon	Van Kempen	University Medical Center Groningen	Netherlands	L.van.kempen@umcg.nl	Molecular pathology, melanoma, NSCLC, nanosting CART profiling
Max	van Min	Cergentis	Netherlands	max.vanmin@cergentis.com	Cergentis' TLA Technology enables the targeted complete NGS sequencing of vectors and integration sites in CAR-T cells.
György	Vereb	University of Debrecen	Hungary	vereb@med.unideb.hu	Generate and characterize at molecular, microscopic and in vitro + in vivo functional levels transgenic (CAR, BiTE) immune cells
Alessandra	Veronese		Italy	veronal2710@gmail.com	Strong knowledge of drugs and medical devices development, long term experience as caregiver for Parkinson and Cancer patients.
Xenia	Villalobos	VHIO - Research Coordination and Innovation Unit	Spain	xvillalobos@vhio.net	We focus on global project management, supporting project writing, execution and follow-up, and supervising IP issues

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Scott	Wagers	Biosci Consulting	Belgium	scottwagers@biosciconsulting.com	Facilitating multi-stakeholder dialogues to develop projects, manage consortia, and plan sustainability
Sébastien	Wälchli	OUH	Norway	sebastw@rr-research.no	CAR pre-clinical development, molecular biology
Agnese	Winfield	nanosting	United Kingdom	awinfield@nanosting.com	I am part of the nanosting team sponsoring the IMI project for the CAR-T part with CAR-T specific gene expression panels
xiaoqian	wu			wuxiaoqian@cs-biotech.com	Feedback from CAR-T users
Anja	Zagorac	Biomedica Medizinprodukte GmbH	Serbia	anja.zagorac@bmgrp.rs	12 year in oncology pharma and diagnostic expertise